Survey on the impact of COVID19 in patients on immunosuppression for ocular and orbital inflammatory disorders

Eur J Ophthalmol. 2022 Jan;32(1):NP280-NP282. doi: 10.1177/11206721211008039. Epub 2021 Apr 8.

Authors

Mervyn G Thomas^{1

2}, Periyasamy Kumar¹, Tahir Islam¹, Helen J Kuht², Tharsica Sivagnanasithiyar¹, Carol Betteridge¹, Arumugam Moorthy³, Bharat Kapoor¹

Affiliations

¹ Department of Ophthalmology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK.
² The University of Leicester Ulverscroft Eye Unit, Department of Neuroscience, Psychology and Behaviour, University of Leicester, RKCSB, Leicester, UK.
³ Department of Rheumatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK.

PMID: 33832345
DOI: 10.1177/11206721211008039

No abstract available

MeSH terms

COVID-19*
Eye
Humans
Immunosuppression Therapy
Orbital Diseases* / drug therapy
SARS-CoV-2

Grants and funding

CL-2017-11-003/DH_/Department of Health/United Kingdom